MicroVention Terumo

About MicroVention Terumo

Originally established as MicroVention in 1997 and rebranded to Terumo Neuro in 2024, the company operates as a key entity within the global neurovascular market. Its journey began when founders Bob Rosenbluth, Brian Cox, and Rob Greene started the company in Southern California with a vision to develop treatments for cerebrovascular diseases. Rosenbluth, a serial entrepreneur in the medical device sector with a Ph.D. in Mechanical Engineering, served as the initial President and CEO, bringing extensive experience from roles at Medtronic and Pfizer.

A pivotal moment in the company's history was its acquisition by Tokyo-based Terumo Corporation in 2006. This strategic integration provided MicroVention with substantial resources to scale its operations and innovation pipeline while retaining its agile and entrepreneurial culture. The business model centers on the development, manufacturing, and sale of medical devices to neurovascular surgeons and hospitals worldwide. Revenue is generated through direct sales in over 70 countries and strategic distribution partnerships, supported by manufacturing facilities in California and Costa Rica.

Terumo Neuro's product portfolio is comprehensive, addressing both hemorrhagic and ischemic strokes, cerebral aneurysms, carotid artery disease, and other neurovascular malformations. Initially focused on aneurysm therapy, the company launched a first-of-its-kind hydrogel coil in 2002. Its offerings have since expanded to include over 30 distinct products. Key product families include the SOFIA™ catheters, known for their trackability; the ERIC™ Retrieval Device for ischemic stroke treatment; and the WEB™ Aneurysm Embolization System, which is based on a proprietary mesh design. The company also provides a full suite of access products like balloon guide catheters, guidewires, and microcatheters designed to help physicians reach treatment sites in the brain's complex vascular structure. The recent rebranding to Terumo Neuro signals a strategic expansion beyond its core stroke focus to encompass the broader neurovascular patient care continuum, exploring areas like electrical stimulation for post-stroke recovery.